Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung Biologics Adopts Solentim Solutions in R&D Center | Contract Pharma

What are you searching for?

Sign in
Breaking News

Samsung Biologics Adopts Solentim Solutions in R&D Center

Solentim’s instruments will be used in conjunction with Samsung Biologics’ proprietary cell line platform.

By: Contract Pharma

Contract Pharma Staff

Solentim’s VIPS single cell seeding platform and Cell Metric CLD have been adopted into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development.
 
Samsung’s new R&D facility in San Francisco will offer rapid, high-quality development services, including cell line development, to its global customers. Solentim’s VIPS and Cell Metric CLD instruments will be used in conjunction with Samsung Biologics’ recently launched proprietary cell line platform, S-CHOice, announced last month.
 
“We’re pleased to extend our long-standing partnership with Samsung Biologics, which has previously purchased and enjoyed success with our equipment in its headquarter operations,” said Dr. Mark Truesdale, CEO of Solentim.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics